Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Stopped Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No subjects were enrolled.

Conditions

• Urothelial Carcinoma

Interventions

• DRUG: Avelumab
• DRUG: Tuvusertib

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]